CNS vasculitis in a patient with MS on daclizumab monotherapy

Joan Ohayon, Unsong Oh, Nancy Richert, Jayne Martin, Alexander Vortmeyer, Henry McFarland, Bibiana Bielekova

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Objective: To report the development of CNS vasculitis in a patientwithmultiple sclerosis (MS) treated with daclizumab. Methods: This report includes clinical, MRI, immunologic, and pathology data and CSF analysis. Results: After completing a phase II daclizumab monotherapy study with an optimal response as evidenced by significant decrease in MRI disease activity and stable clinical examinations, the patient elected to continue daclizumab therapy outside of NIH study. Daclizumab was discontinued after 21 doses due to the onset of new clinical symptoms and evidence of a vascular pattern of contrast enhancement on brain and spine MRI. Because of continued clinical deterioration, stereotactic brain biopsy was performed, showing small-vessel CNS vasculitis. Treatment was initiated with IV methylprednisolone followed by a regimen of cyclophosphamide. Immunologic studies suggest that unexpected lack of expansion of CD56bright NK cells and predictable decline in FoxP31 T-regs combined with a transient interruption in daclizumab dosing may have contributed to this serious side effect. Conclusions: Only safety data from larger phase III studies and potentially postmarketing experience will define the exact risk of daclizumab-induced immunopathologies. Nevertheless, our case provides plausible hypothesis and potential biomarker that may be used to screen susceptible patients and implement preventive safety measures during potentially vulnerable periods.

Original languageEnglish (US)
Pages (from-to)453-457
Number of pages5
JournalNeurology
Volume80
Issue number5
DOIs
StatePublished - Jan 29 2013
Externally publishedYes

Fingerprint

Central Nervous System Vasculitis
Safety
Methylprednisolone
Brain
Sclerosis
Natural Killer Cells
Cyclophosphamide
Blood Vessels
daclizumab
Spine
Biomarkers
Pathology
Biopsy
Therapeutics

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Ohayon, J., Oh, U., Richert, N., Martin, J., Vortmeyer, A., McFarland, H., & Bielekova, B. (2013). CNS vasculitis in a patient with MS on daclizumab monotherapy. Neurology, 80(5), 453-457. https://doi.org/10.1212/WNL.0b013e31827f0f42

CNS vasculitis in a patient with MS on daclizumab monotherapy. / Ohayon, Joan; Oh, Unsong; Richert, Nancy; Martin, Jayne; Vortmeyer, Alexander; McFarland, Henry; Bielekova, Bibiana.

In: Neurology, Vol. 80, No. 5, 29.01.2013, p. 453-457.

Research output: Contribution to journalArticle

Ohayon, J, Oh, U, Richert, N, Martin, J, Vortmeyer, A, McFarland, H & Bielekova, B 2013, 'CNS vasculitis in a patient with MS on daclizumab monotherapy', Neurology, vol. 80, no. 5, pp. 453-457. https://doi.org/10.1212/WNL.0b013e31827f0f42
Ohayon J, Oh U, Richert N, Martin J, Vortmeyer A, McFarland H et al. CNS vasculitis in a patient with MS on daclizumab monotherapy. Neurology. 2013 Jan 29;80(5):453-457. https://doi.org/10.1212/WNL.0b013e31827f0f42
Ohayon, Joan ; Oh, Unsong ; Richert, Nancy ; Martin, Jayne ; Vortmeyer, Alexander ; McFarland, Henry ; Bielekova, Bibiana. / CNS vasculitis in a patient with MS on daclizumab monotherapy. In: Neurology. 2013 ; Vol. 80, No. 5. pp. 453-457.
@article{5d9dd0dea071494eb1c9f0dbcd514c8c,
title = "CNS vasculitis in a patient with MS on daclizumab monotherapy",
abstract = "Objective: To report the development of CNS vasculitis in a patientwithmultiple sclerosis (MS) treated with daclizumab. Methods: This report includes clinical, MRI, immunologic, and pathology data and CSF analysis. Results: After completing a phase II daclizumab monotherapy study with an optimal response as evidenced by significant decrease in MRI disease activity and stable clinical examinations, the patient elected to continue daclizumab therapy outside of NIH study. Daclizumab was discontinued after 21 doses due to the onset of new clinical symptoms and evidence of a vascular pattern of contrast enhancement on brain and spine MRI. Because of continued clinical deterioration, stereotactic brain biopsy was performed, showing small-vessel CNS vasculitis. Treatment was initiated with IV methylprednisolone followed by a regimen of cyclophosphamide. Immunologic studies suggest that unexpected lack of expansion of CD56bright NK cells and predictable decline in FoxP31 T-regs combined with a transient interruption in daclizumab dosing may have contributed to this serious side effect. Conclusions: Only safety data from larger phase III studies and potentially postmarketing experience will define the exact risk of daclizumab-induced immunopathologies. Nevertheless, our case provides plausible hypothesis and potential biomarker that may be used to screen susceptible patients and implement preventive safety measures during potentially vulnerable periods.",
author = "Joan Ohayon and Unsong Oh and Nancy Richert and Jayne Martin and Alexander Vortmeyer and Henry McFarland and Bibiana Bielekova",
year = "2013",
month = "1",
day = "29",
doi = "10.1212/WNL.0b013e31827f0f42",
language = "English (US)",
volume = "80",
pages = "453--457",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - CNS vasculitis in a patient with MS on daclizumab monotherapy

AU - Ohayon, Joan

AU - Oh, Unsong

AU - Richert, Nancy

AU - Martin, Jayne

AU - Vortmeyer, Alexander

AU - McFarland, Henry

AU - Bielekova, Bibiana

PY - 2013/1/29

Y1 - 2013/1/29

N2 - Objective: To report the development of CNS vasculitis in a patientwithmultiple sclerosis (MS) treated with daclizumab. Methods: This report includes clinical, MRI, immunologic, and pathology data and CSF analysis. Results: After completing a phase II daclizumab monotherapy study with an optimal response as evidenced by significant decrease in MRI disease activity and stable clinical examinations, the patient elected to continue daclizumab therapy outside of NIH study. Daclizumab was discontinued after 21 doses due to the onset of new clinical symptoms and evidence of a vascular pattern of contrast enhancement on brain and spine MRI. Because of continued clinical deterioration, stereotactic brain biopsy was performed, showing small-vessel CNS vasculitis. Treatment was initiated with IV methylprednisolone followed by a regimen of cyclophosphamide. Immunologic studies suggest that unexpected lack of expansion of CD56bright NK cells and predictable decline in FoxP31 T-regs combined with a transient interruption in daclizumab dosing may have contributed to this serious side effect. Conclusions: Only safety data from larger phase III studies and potentially postmarketing experience will define the exact risk of daclizumab-induced immunopathologies. Nevertheless, our case provides plausible hypothesis and potential biomarker that may be used to screen susceptible patients and implement preventive safety measures during potentially vulnerable periods.

AB - Objective: To report the development of CNS vasculitis in a patientwithmultiple sclerosis (MS) treated with daclizumab. Methods: This report includes clinical, MRI, immunologic, and pathology data and CSF analysis. Results: After completing a phase II daclizumab monotherapy study with an optimal response as evidenced by significant decrease in MRI disease activity and stable clinical examinations, the patient elected to continue daclizumab therapy outside of NIH study. Daclizumab was discontinued after 21 doses due to the onset of new clinical symptoms and evidence of a vascular pattern of contrast enhancement on brain and spine MRI. Because of continued clinical deterioration, stereotactic brain biopsy was performed, showing small-vessel CNS vasculitis. Treatment was initiated with IV methylprednisolone followed by a regimen of cyclophosphamide. Immunologic studies suggest that unexpected lack of expansion of CD56bright NK cells and predictable decline in FoxP31 T-regs combined with a transient interruption in daclizumab dosing may have contributed to this serious side effect. Conclusions: Only safety data from larger phase III studies and potentially postmarketing experience will define the exact risk of daclizumab-induced immunopathologies. Nevertheless, our case provides plausible hypothesis and potential biomarker that may be used to screen susceptible patients and implement preventive safety measures during potentially vulnerable periods.

UR - http://www.scopus.com/inward/record.url?scp=84873661188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873661188&partnerID=8YFLogxK

U2 - 10.1212/WNL.0b013e31827f0f42

DO - 10.1212/WNL.0b013e31827f0f42

M3 - Article

VL - 80

SP - 453

EP - 457

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 5

ER -